Posts With Tag non-small cell lung cancer

AstraZeneca's Tagrisso receives EU approval for NSCLC, showing 39.1 months PFS in LAURA trial. A game-changer for lung cancer patients with EGFR mutations.

Explore Affimed N.V.'s latest 6-K filing detailing significant clinical trial updates for AFM24, safety profile, efficacy results, and a robust cash position projected into 2025.